{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:22:58Z","timestamp":1772166178005,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-024-03609-w","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T09:21:59Z","timestamp":1734686519000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of neoadjuvant S-1-based chemoradiotherapy in resectable and borderline-resectable pancreatic cancer: a long-term follow-up study"],"prefix":"10.1186","volume":"22","author":[{"given":"Gaku","family":"Shimane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Kitago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Aiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shutaro","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Fukada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Masugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"issue":"1","key":"3609_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334. https:\/\/doi.org\/10.3322\/caac.21551.","journal-title":"CA Cancer J Clin"},{"key":"3609_CR2","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/jjco\/hyv088","volume":"45","author":"M Hori","year":"2015","unstructured":"Hori M, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, et al. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2015;45:884\u201391. https:\/\/doi.org\/10.1093\/jjco\/hyv088.","journal-title":"Jpn J Clin Oncol"},{"key":"3609_CR3","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893\u2013917. https:\/\/doi.org\/10.1002\/ijc.25516.","journal-title":"Int J Cancer"},{"key":"3609_CR4","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1200\/JCO.2007.15.8634","volume":"26","author":"DB Evans","year":"2008","unstructured":"Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496\u2013502. https:\/\/doi.org\/10.1200\/JCO.2007.15.8634.","journal-title":"J Clin Oncol"},{"key":"3609_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","volume":"268","author":"J Jang","year":"2018","unstructured":"Jang J, Han Y, Lee H, Kim S, Kwon W, Lee K, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial. Ann Surg. 2018;268:215\u201322. https:\/\/doi.org\/10.1097\/SLA.0000000000002705.","journal-title":"Ann Surg"},{"key":"3609_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11605-011-1748-7","volume":"16","author":"MH Katz","year":"2012","unstructured":"Katz MH, Wang H, Balachandran A, Bhosale P, Crane CH, Wang X, et al. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg. 2012;16:68\u201378. https:\/\/doi.org\/10.1007\/s11605-011-1748-7. discussion -9.","journal-title":"J Gastrointest Surg"},{"key":"3609_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12957-019-1687-4","volume":"17","author":"Y Endo","year":"2019","unstructured":"Endo Y, Kitago M, Aiura K, Shinoda M, Yagi H, Abe Y, et al. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study. World J Surg Oncol. 2019;17:145. https:\/\/doi.org\/10.1186\/s12957-019-1687-4. Epub 2019\/08\/20.","journal-title":"World J Surg Oncol"},{"issue":"10","key":"3609_CR8","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1002\/cam4.1178","volume":"6","author":"Y Nakano","year":"2017","unstructured":"Nakano Y, Kitago M, Shinoda M, Abe Y, Yagi H, Hibi T, et al. Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study. Cancer Med. 2017;6(10):2278\u201386. https:\/\/doi.org\/10.1002\/cam4.1178.","journal-title":"Cancer Med"},{"key":"3609_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2302\/kjm.2014-0014-CR","volume":"64","author":"Y Fujii-Nishimura","year":"2015","unstructured":"Fujii-Nishimura Y, Nishiyama R, Kitago M, Masugi Y, Ueno A, Aiura K, et al. Two cases of pathological complete response to neoadjuvant chemoradiation therapy in pancreatic cancer. Keio J Med. 2015;64:26\u201331. https:\/\/doi.org\/10.2302\/kjm.2014-0014-CR.","journal-title":"Keio J Med"},{"key":"3609_CR10","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","volume":"31","author":"H Ueno","year":"2013","unstructured":"Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013;31:1640\u20138. https:\/\/doi.org\/10.1200\/JCO.2012.43.3680.","journal-title":"J Clin Oncol"},{"key":"3609_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000086771","volume":"68","author":"H Ueno","year":"2005","unstructured":"Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology. 2005;68:171\u20138. https:\/\/doi.org\/10.1159\/000086771.","journal-title":"Oncology"},{"key":"3609_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00280-007-0514-8","volume":"61","author":"T Okusaka","year":"2008","unstructured":"Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S, et al. A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2008;61:615\u201321. https:\/\/doi.org\/10.1007\/s00280-007-0514-8.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3609_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin. 2017;67:93\u20139. https:\/\/doi.org\/10.3322\/caac.21388.","journal-title":"CA Cancer J Clin"},{"key":"3609_CR14","volume-title":"Classification of pancreatic carcinoma","author":"Japan Pancreas Society","year":"2017","unstructured":"Japan Pancreas Society. Classification of pancreatic carcinoma. 4th ed. Tokyo: Kanehara; 2017.","edition":"4"},{"key":"3609_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","volume":"19","author":"MA Tempero","year":"2021","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:439\u201357. https:\/\/doi.org\/10.6004\/jnccn.2021.0017.","journal-title":"J Natl Compr Canc Netw"},{"key":"3609_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41379-020-00683-9","volume":"34","author":"BV Janssen","year":"2021","unstructured":"Janssen BV, Tutucu F, van Roessel S, Adsay V, Basturk O, Campbell F, et al. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Mod Pathol. 2021;34:4\u201312. https:\/\/doi.org\/10.1038\/s41379-020-00683-9.","journal-title":"Mod Pathol"},{"key":"3609_CR17","unstructured":"National Cancer Institute NIoH, US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. NIH publication 09\u20137473. Published May 29, 2009; Revised June 14, 2010. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 16 Mar 2015."},{"key":"3609_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"3609_CR19","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s00423-023-02914-4","volume":"408","author":"Y Nakano","year":"2023","unstructured":"Nakano Y, Endo Y, Kitago M, Nishiyama R, Yagi H, Abe Y, et al. Clinical characteristics and predictive factors of postoperative intra-abdominal abscess after distal pancreatectomy. Langenbecks Arch Surg. 2023;408:170. https:\/\/doi.org\/10.1007\/s00423-023-02914-4.","journal-title":"Langenbecks Arch Surg"},{"key":"3609_CR20","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1007\/s00268-021-06076-6","volume":"45","author":"Y Endo","year":"2021","unstructured":"Endo Y, Kitago M, Shinoda M, Yagi H, Abe Y, Oshima G, et al. Clinical impact of portal vein distance on computed tomography for postoperative pancreatic fistula after pancreatoduodenectomy. World J Surg. 2021;45:2200\u20139. https:\/\/doi.org\/10.1007\/s00268-021-06076-6.","journal-title":"World J Surg"},{"key":"3609_CR21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1159\/000244265","volume":"10","author":"K Aiura","year":"2010","unstructured":"Aiura K, Takahashi S, Matsui J, Ueda M, Kitagawa Y. Beneficial effects of 5-Fluorouracil and heparin-based portal infusion chemotherapy combined with mitomycin C and cisplatin after curative resection of pancreatic cancer. Pancreatology. 2010;10:250\u20138. https:\/\/doi.org\/10.1159\/000244265.","journal-title":"Pancreatology"},{"issue":"46","key":"3609_CR22","doi-asserted-by":"publisher","first-page":"e35856","DOI":"10.1097\/MD.0000000000035856","volume":"102","author":"K Hayashi","year":"2023","unstructured":"Hayashi K, Kitago M, Abe Y, Yagi H, Hasegawa Y, Hori S, et al. Long-term survival after surgical resection for bone metastasis from pancreatic cancer: a case report. Medicine (Baltimore). 2023;102(46):e35856.","journal-title":"Medicine (Baltimore)"},{"key":"3609_CR23","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1007\/s11605-015-2890-4","volume":"19","author":"R Casadei","year":"2015","unstructured":"Casadei R, Di Marco M, Ricci C, Santini D, Serra C, Calculli L, et al. Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg. 2015;19:1802\u201312. https:\/\/doi.org\/10.1007\/s11605-015-2890-4.","journal-title":"J Gastrointest Surg"},{"key":"3609_CR24","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1200\/JCO.19.02274","volume":"38","author":"E Versteijne","year":"2020","unstructured":"Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38:1763\u201373. https:\/\/doi.org\/10.1200\/JCO.19.02274.","journal-title":"J Clin Oncol"},{"key":"3609_CR25","doi-asserted-by":"publisher","unstructured":"Takahashi S, Ohno I, Ikeda M, Konishi M, Kobayashi T, Akimoto T, et al. Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: a Phase II open-label multicenter prospective trial (JASPAC05). Ann Surg. 2020. https:\/\/doi.org\/10.1097\/SLA.0000000000004535.","DOI":"10.1097\/SLA.0000000000004535"},{"key":"3609_CR26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ags3.12624","volume":"7","author":"M Matsumura","year":"2023","unstructured":"Matsumura M, Honda G, Tani K, Nemoto S, Ome Y, Hayakawa S, et al. The outcome of a multidisciplinary approach incorporating neoadjuvant chemoradiotherapy with S1 for resectable pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 2023;7:306\u201317. https:\/\/doi.org\/10.1002\/ags3.12624.","journal-title":"Ann Gastroenterol Surg"},{"key":"3609_CR27","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s11605-011-1795-0","volume":"16","author":"S Satoi","year":"2012","unstructured":"Satoi S, Toyokawa H, Yanagimoto H, Yamamoto T, Kamata M, Ohe C, et al. Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer. J Gastrointest Surg. 2012;16:784\u201392. https:\/\/doi.org\/10.1007\/s11605-011-1795-0.","journal-title":"J Gastrointest Surg"},{"key":"3609_CR28","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/COC.0000000000000688","volume":"43","author":"K Thanikachalam","year":"2020","unstructured":"Thanikachalam K, Damarla V, Seixas T, Dobrosotskaya I, Wollner I, Kwon D, et al. Neoadjuvant phase II trial of chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer. Am J Clin Oncol. 2020;43:435\u201341. https:\/\/doi.org\/10.1097\/COC.0000000000000688.","journal-title":"Am J Clin Oncol"},{"key":"3609_CR29","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.3390\/nu13103522","volume":"13","author":"G Rovesti","year":"2021","unstructured":"Rovesti G, Valoriani F, Rimini M, Bardasi C, Ballarin R, Di Benedetto F, et al. Clinical implications of malnutrition in the management of patients with pancreatic cancer: introducing the concept of the nutritional oncology board. Nutrients. 2021;13:3522. https:\/\/doi.org\/10.3390\/nu13103522.","journal-title":"Nutrients"},{"key":"3609_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12957-024-03310-y","volume":"22","author":"C Liu","year":"2024","unstructured":"Liu C, An L, Zhang S, Deng S, Wang N, Tang H. Association between preoperative sarcopenia and prognosis of pancreatic cancer after curative-intent surgery: a updated systematic review and meta-analysis. World J Surg Oncol. 2024;22:38.","journal-title":"World J Surg Oncol"},{"key":"3609_CR31","doi-asserted-by":"publisher","first-page":"885","DOI":"10.4240\/wjgs.v13.i9.885","volume":"13","author":"I Trestini","year":"2021","unstructured":"Trestini I, Cintoni M, Rinninella E, Grassi F, Paiella S, Salvia R, et al. Neoadjuvant treatment: a window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma. World J Gastrointest Surg. 2021;13:885\u2013903. https:\/\/doi.org\/10.4240\/wjgs.v13.i9.885.","journal-title":"World J Gastrointest Surg"},{"key":"3609_CR32","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ejso.2022.12.006","volume":"49","author":"R De Luca","year":"2023","unstructured":"De Luca R, Gianotti L, Pedrazzoli P, Brunetti O, Rizzo A, Sandini M, et al. Immunonutrition and prehabilitation in pancreatic cancer surgery: a new concept in the era of ERAS(R) and neoadjuvant treatment. Eur J Surg Oncol. 2023;49:542\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2022.12.006.","journal-title":"Eur J Surg Oncol"},{"key":"3609_CR33","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1200\/JCO.2014.59.1081","volume":"33","author":"H van Waart","year":"2015","unstructured":"van Waart H, Stuiver MM, van Harten WH, Geleijn E, Kieffer JM, Buffart LM, et al. Effect of low-intensity physical activity and moderate- to high-intensity physical exercise during adjuvant chemotherapy on physical fitness, fatigue, and chemotherapy completion rates: results of the PACES randomized clinical trial. J Clin Oncol. 2015;33:1918\u201327. https:\/\/doi.org\/10.1200\/JCO.2014.59.1081.","journal-title":"J Clin Oncol"},{"key":"3609_CR34","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","volume":"40","author":"E Versteijne","year":"2022","unstructured":"Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;40:1220\u201330. https:\/\/doi.org\/10.1200\/JCO.21.02233.","journal-title":"J Clin Oncol"},{"key":"3609_CR35","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1093\/annonc\/mdp015","volume":"20","author":"R Le Scodan","year":"2009","unstructured":"Le Scodan R, Mornex F, Girard N, Mercier C, Valette PJ, Ychou M, et al. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Ann Oncol. 2009;20:1387\u201396. https:\/\/doi.org\/10.1093\/annonc\/mdp015.","journal-title":"Ann Oncol"},{"key":"3609_CR36","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/cam4.1071","volume":"6","author":"HX Zhan","year":"2017","unstructured":"Zhan HX, Xu JW, Wu D, Wu ZY, Wang L, Hu SY, et al. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. Cancer Med. 2017;6:1201\u201319. https:\/\/doi.org\/10.1002\/cam4.1071.","journal-title":"Cancer Med"},{"key":"3609_CR37","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/SLA.0000000000002432","volume":"266","author":"JR Delpero","year":"2017","unstructured":"Delpero JR, Jeune F, Bachellier P, Regenet N, Le Treut YP, Paye F, et al. Prognostic value of resection margin involvement after pancreaticoduodenectomy for ductal adenocarcinoma: updates from a French prospective multicenter study. Ann Surg. 2017;266:787\u201396. https:\/\/doi.org\/10.1097\/SLA.0000000000002432.","journal-title":"Ann Surg"},{"key":"3609_CR38","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1002\/bjs.11295","volume":"106","author":"M Tanaka","year":"2019","unstructured":"Tanaka M, Mihaljevic AL, Probst P, Heckler M, Klaiber U, Heger U, et al. Meta-analysis of recurrence pattern after resection for pancreatic cancer. Br J Surg. 2019;106:1590\u2013601. https:\/\/doi.org\/10.1002\/bjs.11295.","journal-title":"Br J Surg"},{"key":"3609_CR39","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/hpb.12154","volume":"16","author":"CW Tzeng","year":"2014","unstructured":"Tzeng CW, Balachandran A, Ahmad M, Lee JE, Krishnan S, Wang H, et al. Serum carbohydrate antigen 19\u20139 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014;16:430\u20138. https:\/\/doi.org\/10.1111\/hpb.12154.","journal-title":"HPB (Oxford)"},{"key":"3609_CR40","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/SLA.0000000000003284","volume":"273","author":"MJ Truty","year":"2021","unstructured":"Truty MJ, Kendrick ML, Nagorney DM, Smoot RL, Cleary SP, Graham RP, et al. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline\/locally advanced pancreatic cancer. Ann Surg. 2021;273:341\u20139. https:\/\/doi.org\/10.1097\/SLA.0000000000003284.","journal-title":"Ann Surg"},{"issue":"12","key":"3609_CR41","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1002\/cam4.3044","volume":"9","author":"T Yokose","year":"2020","unstructured":"Yokose T, Kitago M, Matsusaka Y, Masugi Y, Shinoda M, Yagi H, et al. Usefulness of 18 F-fluorodeoxyglucose positron emission tomography\/computed tomography for predicting the prognosis and treatment response of neoadjuvant therapy for pancreatic ductal adenocarcinoma. Cancer Med. 2020;9(12):4059\u201368. https:\/\/doi.org\/10.1002\/cam4.3044.","journal-title":"Cancer Med"},{"key":"3609_CR42","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1245\/s10434-014-4021-y","volume":"22","author":"G Luo","year":"2015","unstructured":"Luo G, Guo M, Liu Z, Xiao Z, Jin K, Long J, et al. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Ann Surg Oncol. 2015;22:670\u20136. https:\/\/doi.org\/10.1245\/s10434-014-4021-y.","journal-title":"Ann Surg Oncol"},{"key":"3609_CR43","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1038\/s41416-022-01745-2","volume":"126","author":"D Pietrasz","year":"2022","unstructured":"Pietrasz D, Sereni E, Lancelotti F, Pea A, Luchini C, Innamorati G, et al. Circulating tumour DNA: a challenging innovation to develop \u201cprecision onco-surgery\u201d in pancreatic adenocarcinoma. Br J Cancer. 2022;126:1676\u201383. https:\/\/doi.org\/10.1038\/s41416-022-01745-2.","journal-title":"Br J Cancer"},{"key":"3609_CR44","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/bjc.2017.479","volume":"118","author":"Y Nakano","year":"2018","unstructured":"Nakano Y, Kitago M, Matsuda S, Nakamura Y, Fujita Y, Imai S, et al. KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study. Br J Cancer. 2018;118:662\u20139. https:\/\/doi.org\/10.1038\/bjc.2017.479.","journal-title":"Br J Cancer"},{"key":"3609_CR45","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1111\/cas.14425","volume":"111","author":"T Yokose","year":"2020","unstructured":"Yokose T, Kitago M, Matsuda S, Sasaki Y, Masugi Y, Nakamura Y, et al. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer. Cancer Sci. 2020;111:2174\u201382. https:\/\/doi.org\/10.1111\/cas.14425.","journal-title":"Cancer Sci"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03609-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-024-03609-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03609-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T10:03:25Z","timestamp":1734689005000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-024-03609-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3609"],"URL":"https:\/\/doi.org\/10.1186\/s12957-024-03609-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4873302\/v1","asserted-by":"object"}]},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"7 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The study design was approved by the Institutional Review Board of Keio University School of Medicine (#20090127). Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"336"}}